OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001427570

Vyome Holdings, Inc (HIND)

Vyome Holdings, Inc (CIK 0001427570, ticker HIND) reported revenue of $319,714 for FY2025 (2025-01-01 to 2025-12-31) and net income of -$10.26 million (-$10,262,007) for FY2025 (2025-01-01 to 2025-12-31), as filed in its 10-K filed 2026-03-18 (accession 0001213900-26-029500).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001427570
TickersHIND (Nasdaq)
EINnot in EDGAR (or not a valid EIN)
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer category<br>Emerging growth company
Entity typeoperating
Olympus entity IDorg_2kg14914cxf59695x8kb6b4hfw
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$319,714FY20252025-01-01 to 2025-12-3110-K2026-03-180001213900-26-029500Revenues
Net income-$10,262,007FY20252025-01-01 to 2025-12-3110-K2026-03-180001213900-26-029500NetIncomeLoss
Total assets$6,497,177FY2025as of 2025-12-3110-K2026-03-180001213900-26-029500Assets
Total liabilities$2,735,160FY2025as of 2025-12-3110-K2026-03-180001213900-26-029500Liabilities
Stockholders' equity$3,762,017FY2025as of 2025-12-3110-K2026-03-180001213900-26-029500StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Operating cash flow-$3,748,853FY20252025-01-01 to 2025-12-3110-K2026-03-180001213900-26-029500NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$4.86 per shareFY20252025-01-01 to 2025-12-3110-K2026-03-180001213900-26-029500EarningsPerShareDiluted
Shares outstanding7,018,528 sharesFY2025as of 2026-03-1710-K2026-03-180001213900-26-029500EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2016-2025, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20252025-01-01 to 2025-12-31$319,71410-K2026-03-180001213900-26-029500
RevenueFY20242024-01-01 to 2024-12-31$256,94410-K2026-03-180001213900-26-029500
RevenueFY20232023-01-01 to 2023-12-31$8,678,00010-K2025-04-040001558370-25-004477
RevenueFY20222022-01-01 to 2022-12-31$11,240,00010-K2024-04-010001558370-24-004559
RevenueFY20212021-01-01 to 2021-12-31$13,600,00010-K2023-04-170001558370-23-006079
RevenueFY20202020-01-01 to 2020-12-31$11,299,00010-K2022-04-080001558370-22-005238
RevenueFY20192019-01-01 to 2019-12-31$3,281,00010-K2021-03-120001558370-21-002923
RevenueFY20182018-01-01 to 2018-12-31$9,101,00010-K2019-02-220001427570-19-000019
RevenueFY20172017-01-01 to 2017-12-31$9,914,00010-K2019-02-220001427570-19-000019
RevenueFY20162016-01-01 to 2016-12-31$3,393,00010-K2018-03-050001427570-18-000013
Net incomeFY20252025-01-01 to 2025-12-31-$10,262,00710-K2026-03-180001213900-26-029500
Net incomeFY20242024-01-01 to 2024-12-31-$1,447,46110-K2026-03-180001213900-26-029500
Net incomeFY20232023-01-01 to 2023-12-31-$11,387,00010-K2025-04-040001558370-25-004477
Net incomeFY20222022-01-01 to 2022-12-31-$46,214,00010-K2024-04-010001558370-24-004559
Net incomeFY20212021-01-01 to 2021-12-31-$63,146,00010-K2023-04-170001558370-23-006079
Net incomeFY20202020-01-01 to 2020-12-31-$21,630,00010-K2022-04-080001558370-22-005238
Net incomeFY20192019-01-01 to 2019-12-31-$23,676,00010-K2021-03-120001558370-21-002923
Net incomeFY20182018-01-01 to 2018-12-31-$37,380,00010-K2020-02-270001427570-20-000018
Net incomeFY20172017-01-01 to 2017-12-31-$34,765,00010-K2019-02-220001427570-19-000019
Net incomeFY20162016-01-01 to 2016-12-31-$20,467,00010-K2018-03-050001427570-18-000013
  • Revenue for FY2020 was restated: first reported as $1,588,000 (accession 0001558370-21-002923, filed 2021-03-12).
  • Net income for FY2024 was restated: first reported as -$7,130,000 (accession 0001558370-25-004477, filed 2025-04-04).
  • Net income for FY2021 was restated: first reported as -$61,933,000 (accession 0001558370-22-005238, filed 2022-04-08).
  • Net income for FY2020 was restated: first reported as -$12,334,000 (accession 0001558370-21-002923, filed 2021-03-12).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2026-08-122026-06-300001213900-26-088402ea0300868-10q_vyome.htm
10-Q2026-05-122026-03-310001213900-26-055058ea0289466-10q_vyome.htm
10-K2026-03-182025-12-310001213900-26-029500ea0280821-10k_vyomehold.htm
10-Q2025-11-142025-09-300001213900-25-110980ea0264973-10q_vyome.htm
10-Q2025-08-142025-06-300001558370-25-011594rsls-20250630x10q.htm
10-Q2025-05-202025-03-310001558370-25-008031rsls-20250331x10q.htm
10-K2025-04-042024-12-310001558370-25-004477rsls-20241231x10k.htm
10-Q2024-11-142024-09-300001558370-24-015732rsls-20240930x10q.htm
10-Q2024-08-142024-06-300001558370-24-012246rsls-20240630x10q.htm
10-Q2024-05-152024-03-310001558370-24-008304rsls-20240331x10q.htm
10-K2024-04-012023-12-310001558370-24-004559rsls-20231231x10k.htm
10-Q2023-11-092023-09-300001558370-23-018344rsls-20230930x10q.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001427570published by the sourcedata.sec.gov/submissions/CIK0001427570.json2026-10-21

Former names

NameFromTo
ReShape Lifesciences Inc.2021-06-222025-08-14
OBALON THERAPEUTICS INC2008-02-132021-06-21

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001427570.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001427570.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001427570" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001427570/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001427570/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1427570"}

On SEC EDGAR

About this data